Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer.

Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, McNeel DG.

J Immunother. 2010 Jul-Aug;33(6):639-47. doi: 10.1097/CJI.0b013e3181dda23e.

2.

HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.

Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, McNeel DG.

Cancer Immunol Immunother. 2010 Jun;59(6):943-53. doi: 10.1007/s00262-010-0820-6. Epub 2010 Feb 6.

3.

Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells.

Johnson LE, Frye TP, Chinnasamy N, Chinnasamy D, McNeel DG.

Cancer Immunol Immunother. 2007 Jun;56(6):885-95. Epub 2006 Nov 11.

PMID:
17102977
4.

Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer.

McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R, Liu G, Eickhoff JC, Wilding G.

J Clin Oncol. 2009 Sep 1;27(25):4047-54. doi: 10.1200/JCO.2008.19.9968. Epub 2009 Jul 27.

5.

Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP).

Johnson LE, Frye TP, Arnot AR, Marquette C, Couture LA, Gendron-Fitzpatrick A, McNeel DG.

Vaccine. 2006 Jan 16;24(3):293-303. Epub 2005 Aug 9.

PMID:
16115700
6.

Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes.

Johnson LE, McNeel DG.

Prostate. 2012 May 15;72(7):730-40. doi: 10.1002/pros.21477. Epub 2011 Aug 30.

PMID:
22529020
7.

Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer.

McNeel DG, Becker JT, Eickhoff JC, Johnson LE, Bradley E, Pohlkamp I, Staab MJ, Liu G, Wilding G, Olson BM.

Clin Cancer Res. 2014 Jul 15;20(14):3692-704. doi: 10.1158/1078-0432.CCR-14-0169. Epub 2014 May 21.

8.

Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.

Karan D, Dubey S, Van Veldhuizen P, Holzbeierlein JM, Tawfik O, Thrasher JB.

Immunotherapy. 2011 Jun;3(6):735-46. doi: 10.2217/imt.11.59.

PMID:
21668311
9.

Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.

Machlenkin A, Paz A, Bar Haim E, Goldberger O, Finkel E, Tirosh B, Volovitz I, Vadai E, Lugassy G, Cytron S, Lemonnier F, Tzehoval E, Eisenbach L.

Cancer Res. 2005 Jul 15;65(14):6435-42.

10.

Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade.

Olson BM, Jankowska-Gan E, Becker JT, Vignali DA, Burlingham WJ, McNeel DG.

J Immunol. 2012 Dec 15;189(12):5590-601. doi: 10.4049/jimmunol.1201744. Epub 2012 Nov 14.

11.

Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice.

Saif JM, Vadakekolathu J, Rane SS, McDonald D, Ahmad M, Mathieu M, Pockley AG, Durrant L, Metheringham R, Rees RC, McArdle SE.

Eur J Immunol. 2014 Apr;44(4):994-1004. doi: 10.1002/eji.201343863. Epub 2014 Mar 7.

12.

Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.

Li N, Qin H, Li X, Zhou C, Wang D, Ma W, Lin C, Zhang Y, Wang S, Zhang S.

J Clin Immunol. 2007 Jan;27(1):117-30. Epub 2006 Dec 16.

PMID:
17180470
13.

Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer.

McNeel DG, Nguyen LD, Ellis WJ, Higano CS, Lange PH, Disis ML.

Prostate. 2001 May 15;47(3):222-9.

PMID:
11351352
14.

DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses.

Smith HA, Rekoske BT, McNeel DG.

Vaccine. 2014 Mar 26;32(15):1707-15. doi: 10.1016/j.vaccine.2014.01.048. Epub 2014 Jan 31.

15.

An artificial PAP gene breaks self-tolerance and promotes tumor regression in the TRAMP model for prostate carcinoma.

Spies E, Reichardt W, Alvarez G, Groettrup M, Ohlschläger P.

Mol Ther. 2012 Mar;20(3):555-64. doi: 10.1038/mt.2011.241. Epub 2011 Nov 15.

16.

Identification of T helper epitopes from prostatic acid phosphatase.

McNeel DG, Nguyen LD, Disis ML.

Cancer Res. 2001 Jul 1;61(13):5161-7.

17.

Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens.

Qin H, Zhou C, Wang D, Ma W, Liang X, Lin C, Zhang Y, Zhang S.

Immunol Lett. 2005 Jun 15;99(1):85-93. Epub 2005 Feb 16.

PMID:
15894116
18.

DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.

Vittes GE, Harden EL, Ottensmeier CH, Rice J, Stevenson FK.

Eur J Immunol. 2011 Aug;41(8):2447-56. doi: 10.1002/eji.201141518. Epub 2011 Jul 4.

19.

Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.

Waeckerle-Men Y, Uetz-von Allmen E, Fopp M, von Moos R, Böhme C, Schmid HP, Ackermann D, Cerny T, Ludewig B, Groettrup M, Gillessen S.

Cancer Immunol Immunother. 2006 Dec;55(12):1524-33. Epub 2006 Apr 13.

PMID:
16612599
20.

Supplemental Content

Support Center